Insulatard Penfill (Insulin Human)

Insulin human is chemically identical to the insulin produced by the pancreas. After subcutaneous injection it binds to insulin receptors on muscle, fat and liver cells, activating a cascade that increases glucose uptake, stimulates glycogen synthesis and suppresses hepatic glucose production. This coordinated action lowers circulating blood glucose and helps maintain metabolic balance.

The dose of Insulatard Penfill is individualized. A qualified prescriber determines the total daily units based on the patient’s self‑monitored blood glucose, carbohydrate intake, body weight and clinical response. The dose is then titrated gradually to achieve target glucose levels, and adjustments are made as needed during follow‑up visits.

Insulin human is generally considered the preferred glucose‑lowering agent during pregnancy because it does not cross the placenta in significant amounts. It may be used when the benefits outweigh potential risks. Breastfeeding mothers should also consult their healthcare provider, as insulin is excreted in very small quantities in breast milk and is usually regarded as compatible with nursing.

To order Insulatard Penfill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

The primary alternative to Insulatard Penfill is other basal insulins such as insulin glargine or insulin detemir. All provide long‑acting glucose control, but formulation differences affect onset, peak and duration. Insulin human has a well‑established safety profile and is less expensive in many markets, while newer analogues may offer more predictable pharmacokinetics for some patients.

Insulatard Penfill must be stored in a refrigerator at 2‑8 °C. Keep the pen in its original carton, protect it from direct light, and avoid freezing. If the product has been at room temperature for up to 28 days, it may still be used, but any signs of discoloration, cloudiness or particles require disposal.

Insulatard Penfill is administered by subcutaneous injection using the prefilled pen. The injection site should be rotated among the abdomen, thigh or upper arm to reduce lipodystrophy. Patients are instructed to clean the skin with an alcohol swab, attach a new needle, set the prescribed dose on the pen, and inject at a 90‑degree angle.

The most serious risks associated with Insulatard Penfill include severe hypoglycaemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from urticaria to anaphylaxis. Rarely, patients may develop insulin antibody syndrome or serious injection‑site infections such as necrotising fasciitis. Prompt medical attention is required if any of these events occur.

Insulatard Penfill should not be used by individuals with a known hypersensitivity to human insulin or any of the pen’s excipients. It is also contraindicated in patients experiencing hypoglycaemia unawareness or severe hypoglycaemic episodes without proper supervision. Patients with certain endocrine disorders, such as adrenal insufficiency, should use it only under close medical guidance.